Hyun; Linus

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hyun; Linus.The latest application filed is for "egfr and c-met fibronectin type iii domain binding molecules".

Company Profile

6.11.12

Hyun; Linus - King of Prussia PA
Hyun; Linus - Spring House PA
Hyun; Linus - Radnor PA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
EGFR and C-Met Fibronectin Type III Domain Binding Molecules App 20210206825 - Anderson; Mark ; et al.	2021-07-08
Prostate Specific Membrane Antigen Binding Fibronectin Type Iii Domains App 20210147510 - Cardoso; Rosa ; et al.	2021-05-20
EGFR and c-Met fibronectin type III domain binding molecules Grant 10,954,284 - Anderson , et al. March 23, 2	2021-03-23
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof Grant 10,844,122 - Anderson , et al. November 24, 2	2020-11-24
Prostate specific membrane antigen binding fibronectin type III domains Grant 10,844,111 - Cardoso , et al. November 24, 2	2020-11-24
Cysteine Engineered Fibronectin Type Iii Domain Binding Molecules App 20200325210 - Anderson; Mark ; et al.	2020-10-15
Cysteine engineered fibronectin type III domain binding molecules Grant 10,662,235 - Anderson , et al.	2020-05-26
Cysteine Engineered Fibronectin Type III Domain Binding Molecules App 20170362301 - Anderson; Mark ; et al.	2017-12-21
EGFR and C-Met Fibronectin Type III Domain Binding Molecules App 20170305997 - Anderson; Mark ; et al.	2017-10-26
EGFR and C-Met fibronectin type III domain binding molecules Grant 9,725,497 - Anderson , et al. August 8, 2	2017-08-08
EGFR and c-Met fibronectin type III domain binding molecules Grant 9,695,228 - Mark , et al. July 4, 2	2017-07-04
Prostate Specific Membrane Antigen (PSMA) Bispecific Binding Agents and Uses Thereof App 20160347840 - Anderson; Glenn ; et al.	2016-12-01
Prostate Specific Membrane Antigen Binding Fibronectin Type III Domains App 20160326232 - Rosa; Cardosa ; et al.	2016-11-10
Egfr And C-met Fibronectin Type Iii Domain Binding Molecules App 20140155326 - Mark; Anderson ; et al.	2014-06-05
Egfr And C-met Fibronectin Type Iii Domain Binding Molecules App 20140155325 - Mark; Anderson ; et al.	2014-06-05
Engineered hybrid phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage Grant 8,728,982 - Wang , et al. May 20, 2	2014-05-20
Engineered anti-IL-13 antibodies, compositions, methods and uses Grant 8,399,630 - Swanson , et al. March 19, 2	2013-03-19
Engineered anti-IL-13 antibodies, compositions, methods and uses Grant 8,323,646 - Swanson , et al. December 4, 2	2012-12-04
Engineered Anti-il-13 Antibodies, Compositions, Methods And Uses App 20120045438 - Swanson; Ronald V. ; et al.	2012-02-23
Engineered Phage Vectors For The Design And The Generation Of A Human Non-antibody Peptide Or Protein Phage Library Via Fusion To Pix Of M13 Phage App 20110118144 - Hyun; Linus ; et al.	2011-05-19
Engineered Anti-il-13 Antibodies, Compositions, Methods And Uses App 20100111959 - Swanson; Ronald V. ; et al.	2010-05-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.